NOTV (Inotiv) 12-1 Month Momentum % : 3.62% (As of Dec. 15, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Inotiv 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-15), Inotiv's 12-1 Month Momentum % is 3.62%.

The industry rank for Inotiv's 12-1 Month Momentum % or its related term are showing as below:

NOTV's 12-1 Month Momentum % is ranked better than
66.67% of 228 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.455 vs NOTV: 3.62

Competitive Comparison of Inotiv's 12-1 Month Momentum %

For the Diagnostics & Research subindustry, Inotiv's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inotiv's 12-1 Month Momentum % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Inotiv's 12-1 Month Momentum % falls into.

Inotiv (NAS:NOTV) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inotiv (NAS:NOTV) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Inotiv 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Inotiv's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inotiv Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » 12-1 Month Momentum %

Comparable Companies

MDXH FONR ME VNRX XGN BIOQ BNR PRE ENZ OCX TMO DHR XSWX:LONN A IQV IDXX MTD ILMN WAT NTRA

Traded in Other Exchanges

BS50:Germany

Address

2701 Kent Avenue, West Lafayette, IN, USA, 47906

Website

https://www.inotivco.com

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Executives

John Gregory Beattie	officer: Chief Operating Officer	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Michael Garrett	officer: Chief Commercial Officer	250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter	officer: SVP, Gen. Counsel & Secretary	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
John E Sagartz	director, officer: Chief Strategy Officer	19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
David Landman	director	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Robert Jr. Leasure	director, officer: President and CEO	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor	officer: Chief Financial Officer	3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Arthur Krupp	officer: Chief Human Resources Officer	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford	officer: Chief Human Resources Officer	1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff	director	535 N. COLLEGE DRIVE, CARMEL IN 46032
Jeffrey Brennan Freeman	officer: VP-Finance & Corp. Controller	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Davis Gregory Cole	director	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown	director	250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Scott Cragg	director	660 MADISON AVENUE, NEW YORK NY 10065